Arrowhead Paid $215 Million for a Priority Review Voucher. The Return Math Depends on Three Things.

On August 4, 2026, Arrowhead Pharmaceuticals (NASDAQ: ARWR) told analysts on its fiscal Q2 2026 conference call that the company had acquired a Priority Review Voucher (PRV). On August 8, it disclosed the price: $215 million, paid to an undisclosed seller under an asset purchase agreement expected to close in fiscal Q4 2026.

Arrowhead will apply the voucher to a supplemental new drug application (sNDA) it plans to file before the end of 2026 for plozasiran, a small interfering RNA (siRNA) drug that lowers ApoC-III. Plozasiran is already FDA-approved as Redemplo for familial chylomicronemia syndrome, a rare genetic condition. The sNDA seeks to expand the label to severe hypertriglyceridemia (sHTG), a much larger patient population, on the strength of the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 readouts (79% and 81% median triglyceride reductions at Month 12 versus roughly 27% for placebo, plus statistically significant reductions in acute pancreatitis events).

What the voucher buys is time. A PRV shortens the FDA's new drug application review clock from ten months to six months. That is a four-month acceleration. Arrowhead management told analysts they expect a 3x return on the $215 million by moving the plozasiran sHTG uptake curve forward by that amount.

This piece explains what a Priority Review Voucher is, why it exists, where the secondary market has priced them across the last decade, why Arrowhead was willing to pay this much for one, when the math works for a buyer, and where the program's future is uncertain.

A Priority Review Voucher is a transferable FDA-issued regulatory instrument that lets its holder request priority review on a future new drug application (NDA) or biologics license application (BLA). Priority review shortens the FDA's target review time from ten months (the standard for a non-priority application) to six months.

Congress created three separate PRV programs, each with its own eligibility trigger:

Tropical Disease PRV program (2007). Sponsors that develop a drug for a specific list of tropical diseases (malaria, tuberculosis, leprosy, Chagas disease, several others) earn a voucher when the FDA approves that drug.

Rare Pediatric Disease PRV program (2012). Sponsors that develop a drug for a serious or life-threatening disease that primarily affects fewer than 200,000 US patients aged 18 or under earn a voucher on approval. This is the largest of the three programs by voucher issuance.

Material Threat Medical Countermeasure PRV program (2016). Sponsors that develop a drug intended to address a specific material threat (biological, chemical, radiological, nuclear) earn a voucher on approval.

The voucher is transferable, meaning the sponsor that earned it does not have to use it. It can sell it to another company on the open market. That transferability is the entire point of the design. Congress wanted to create a market incentive for developing drugs for underserved patient populations: earn a voucher, sell it, use the cash to fund more research. The buyer, meanwhile, gets to shave four months off a review timeline for whatever unrelated drug it wants to advance.

One PRV, one priority review request. Once used or sold and used, the voucher is spent.

The PRV secondary market has produced a wide range of prices across its history, and the trend since about 2018 has been mostly downward.

Early transactions were expensive. In August 2015, AbbVie paid $350 million to United Therapeutics for a Rare Pediatric Disease PRV, the highest price on record. That transaction happened when only about half a dozen vouchers had been granted by the FDA and buyers competed for a scarce instrument.

BioMarin has been one of the most active sellers on the secondary market:

• 2014: sold a PRV to Sanofi and Regeneron for $67.5 million, used to accelerate the PCSK9 inhibitor Praluent
• 2017: sold a PRV to an undisclosed buyer for $125 million
• 2022: sold a Rare Pediatric Disease PRV to an undisclosed buyer for $110 million

Sanofi has been active on the buy side as well: $245 million to Knight Therapeutics for a PRV earned on Cholbam approval, used on Praluent.

By the late 2010s, prices had settled into a $100 to $150 million range for most transactions. That range has held, with some year-to-year variation, into the mid-2020s. The $215 million Arrowhead paid in 2026 sits above the recent range, though below the historical peak.

The softening trend has two drivers. First, the supply of vouchers has grown. As of the late 2020s, more than two dozen PRVs have been awarded across the three programs. Second, the tightness of the market has eased. Not every buyer needs one at every moment, and holders who sit on vouchers eventually accept lower offers rather than hold them indefinitely.

Arrowhead paid a premium relative to recent transactions. Two specific dynamics in the plozasiran sHTG situation help explain why.

First, the market is racing. Severe hypertriglyceridemia is a large indication, and Arrowhead is not alone in developing an ApoC-III-targeting therapy. Ionis Pharmaceuticals's olezarsen is an antisense oligonucleotide with the same target and is competing for the same commercial window. A four-month head start matters differently when a rival is running the same clock. If Arrowhead lands approval four months earlier, that is four months of exclusive commercial launch before olezarsen (or another competitor) enters the same physician offices.

Second, plozasiran already has a runway of prescriber and payer experience. Redemplo (the FDA-approved plozasiran product for familial chylomicronemia syndrome) launched in November 2025 and reached fiscal Q3 2026 prescription volume roughly double fiscal Q2. That means physicians who might prescribe the sHTG indication already have familiarity with the mechanism, dosing, and safety profile. An accelerated review delivers more than a piece of paper: it delivers that paper into a channel that is already primed to write prescriptions.

Third, Arrowhead's management explicitly framed the return math. On the fiscal Q2 call, executives said they expected a 3x return on the $215 million by shifting the plozasiran sHTG uptake curve forward by roughly four months. That works out to roughly $645 million in incremental net present value across the launch period, which implies a strong opening-year revenue trajectory in the sHTG indication if the sNDA clears. Analysts building forecasts for the sHTG launch will translate that management framing into their own models, but the anchor is a management team that thinks it can extract $645 million of value out of a four-month clock adjustment.

The general math on a PRV purchase is straightforward. A buyer pays the voucher price up front. In return, the buyer moves an approval date forward by roughly four months. The value of those four months depends on three variables.

Peak annual revenue. The bigger the eventual annual revenue of the target drug, the more valuable each month of accelerated commercial availability. A $2 billion peak product benefits more from four extra months than a $200 million peak product.

Competitive dynamics. If competitors are launching at the same time, the four months can shift market share for the life of the franchise. If the drug is entering an uncontested space, the four months just adds four months of revenue at the tail.

Discount rate. Money now is worth more than money later. A high-cost-of-capital company values acceleration more than a low-cost-of-capital company.

A rough rule of thumb: at typical biotech discount rates, four months of accelerated launch pulls forward roughly 8% to 12% of a product's launch-year revenue, plus modest ongoing benefit from earlier market share capture. A voucher priced at $215 million pencils out for a product with expected launch-year revenue in the $500 million to $1 billion range, more if competition is tight.

Arrowhead's projected 3x return on $215 million suggests management sees plozasiran sHTG launch-year revenue somewhere in the $600 million to $800 million range, or lower launch-year revenue with substantial ongoing competitive-share benefit. Analysts have not yet built consensus sHTG forecasts at that level, so the Arrowhead return projection is somewhat ahead of the sell-side, though not unreasonably so given the SHASTA-3/SHASTA-4 magnitude of effect.

The Arrowhead investment thesis on the PRV assumes plozasiran's sHTG launch pulls off a specific commercial trajectory. Three factors will decide whether that trajectory materializes.

Approval on schedule. The PRV shortens the FDA review clock but does not guarantee approval. Priority review is faster review, not favorable review. Arrowhead still has to submit a complete sNDA package that answers all the questions the FDA has about the sHTG label. Any Complete Response Letter (a CRL, the FDA's formal 'not yet' response) would erase the four-month acceleration and cost the $215 million.

Reimbursement. Severe hypertriglyceridemia is a large indication but has an existing standard of care (fibrates, omega-3 formulations) that payers cover cheaply. Plozasiran will face payer scrutiny about which specific sHTG patients qualify for it. Prior authorization requirements, step therapy, and price negotiation will all shape actual prescription volume in the first commercial year.

Prescriber uptake. Redemplo's familial chylomicronemia launch has been strong (prescription volume roughly doubled in fiscal Q3 versus fiscal Q2), which is a positive signal for the sHTG launch. But sHTG is prescribed by a much broader specialist base (endocrinologists, cardiologists, lipidologists) than familial chylomicronemia (predominantly cardiovascular and rare-disease specialists). Broader physician outreach takes longer to translate into prescriptions.

If any of these three factors underperforms, the $215 million becomes a lower-return investment. If all three deliver on Arrowhead's framing, the return math works out. Analysts covering the stock will start building sHTG launch-year revenue forecasts in late 2026 and early 2027 as the sNDA moves through review.

The PRV programs are also subject to Congressional reauthorization. That policy backdrop matters for anyone thinking about the value of holding versus selling a voucher.

The Rare Pediatric Disease PRV program, the largest of the three by issuance, has been reauthorized several times but has drawn criticism from FDA leadership. The agency's public position has been that vouchers create an administrative burden (the priority-review clock is short, and priority applications compete for the same reviewer capacity as standard applications) without producing clear evidence that the incentive actually drives rare pediatric disease drug development. Independent economic studies have reached mixed conclusions on that question.

Congress has extended the program multiple times but each extension has come with negotiation. If a future extension fails or narrows eligibility, the supply of new vouchers dries up. Holders of unused vouchers could see prices rise in that scenario, but the underlying rare-disease development incentive would disappear.

For a buyer like Arrowhead, this matters mainly at the timing edges. If Congress does not reauthorize the program on schedule, current voucher holders will hold longer waiting for a price rise. That could push prices higher in the short term for buyers who need to move quickly. If Congress does reauthorize, the flow of new supply keeps prices in the current range.

Arrowhead did not disclose whether the seller was motivated by policy uncertainty, but the willingness to move on a $215 million deal in mid-2026 suggests both parties saw the price as clearing at the current supply-demand balance rather than betting heavily on future policy shifts.

For investors and industry observers watching Arrowhead specifically, the PRV purchase sends a few signals worth reading carefully.

Management has confidence in the sNDA package. A company does not spend $215 million to accelerate a review it thinks might get turned down. The PRV commitment is a form of management guidance about sNDA quality and expected approval.

Management has confidence in the launch trajectory. The 3x return projection is an implicit statement that Arrowhead expects substantial sHTG revenue relatively soon after approval. Analysts should treat that framing as directional guidance about the sHTG opportunity.

The competitive dynamics with Ionis are real. A company does not pay a premium to a recent-transaction range unless it thinks the race matters. The four-month head start over olezarsen is priced in.

Cash allocation is signaling. Arrowhead is a commercial-stage company with an early Redemplo launch and a broader RNAi pipeline. Allocating $215 million to a review-clock instrument rather than to another pipeline candidate or a share buyback reflects a specific bet on plozasiran being the near-term value driver. Investors should read that alongside the fiscal Q2 disclosures about ARO-INHBE (Arrowhead's obesity siRNA that showed -9.4% weight loss at Week 16 in combination with tirzepatide versus -4.8% for tirzepatide alone) and the broader pipeline plans.

For observers building a mental model of the RNAi commercial landscape, the transaction is a data point on how much a well-run commercial-stage RNAi company will pay to compress its regulatory calendar. Companies pursuing similar strategies (Alnylam, Ionis, Verve) will read the $215 million as a benchmark for their own future purchases if the option comes up.

Arrowhead's $215 million Priority Review Voucher purchase is one of the largest PRV transactions of the past several years and sits above the recent range of $100 to $150 million. The voucher will shorten the FDA's review of plozasiran's severe hypertriglyceridemia sNDA from ten months to six months, delivering roughly a four-month head start over Ionis's competing olezarsen program and roughly $645 million of projected value creation on Arrowhead's own return math.

The math pencils out if three things happen: the sNDA is complete and clears the FDA on the accelerated clock, payers reimburse plozasiran for a substantial share of the sHTG population without prohibitive prior authorization, and prescribers in the broader cardiovascular and endocrine specialties adopt it quickly enough to build the launch curve Arrowhead is modeling. Each of those is a real question. The PRV pays for time, not certainty.

For the broader industry, the transaction is a market signal that PRV prices have not collapsed, that commercial-stage RNAi companies are willing to spend at scale to compress regulatory calendars, and that the secondary market remains active despite policy uncertainty about the underlying programs. Companies watching this deal are likely already modeling their own voucher-purchase scenarios for the pipelines they intend to accelerate next.